DETORE JAMES M. 4

What Happened

• James M. Detore, Chief Financial Officer of CG Oncology, was granted a derivative award of 90,574 shares (reported at $0.00 per share) on April 15, 2026. The filing reports this as an award/grant (transaction code A); no cash changed hands at grant.
• This is a compensation/award transaction (not an open-market purchase or sale). The award does not represent immediate, fully vested ownership — vesting conditions apply.

Key Details

• Transaction date: 2026-04-15; filing date: 2026-04-16 (timely filing).
• Amount: 90,574 shares reported as a derivative award at $0.00 per share.
• Shares owned after transaction: not specified in the provided filing.
• Footnote (vesting): The award vests over four years beginning April 15, 2026 — 25% vests after 12 months, then the remainder vests in 36 equal monthly installments (see footnote F1).
• No indication in the filing of an immediate sale, tax withholding, or a 10b5-1 plan.

Context

• This award is a deferred/conditional grant (derivative) tied to a multi-year vesting schedule; it becomes valuable to the insider only as portions vest and any applicable exercise or settlement occurs.
• Awards like this are common executive compensation practices and do not by themselves signal an immediate buying or selling decision by the insider.